Tolerability and Quality of Life Aspects with the Anti-Androgen Casodex (IC1176,334) as Monotherapy for Prostate Cancer

Androgen Receptor Gene Amplification in a Recurrent Prostate Cancer after Monotherapy with the Nonsteroidal Potent Antiandrogen Casodex (Bicalutamide) with a Subsequent Favorable Response to Maximal Androgen Blockade

“…In phase I-III trials, Casodex as monotherapy (50 mg/day) has prov en slightly inferior to chemical or surgical castration when time to progression, time to treatment failure or the over all of survival have been measured [10]. However, prelim inary follow-up data from trials using 150 mg daily sug gest that Casodex monotherapy and castration are equally effective [4,[10][11][12][13], at least based on the decrease in PSA concentrations. In our ongoing trial, a dose of 450 mg/day is now being tested.…”

Clinical Progress with a New Antiandrogen, Casodex™ (Bicalutamide)

“…In a randomised comparison with flutamide, both in combination with luteinising hormone-releasing hor mone agonists, Casodex was associated with statistically significantly less diarrhoea [12], Casodex has not been associated with alcohol intolerance, pneumonitis or any problems with light/dark adaptation [15], Moreover, since Casodex is a nonsteroidal antiandrogen, there are no steroidal side effects. Elevations of liver transami nases have been seen with Casodex, but these are usually transient, resolving either on continued therapy or on temporary cessation of therapy.…”

Health related quality of life in prostate carcinoma patients

“…Publications cited in Table 1 Related publications dealing with the same trial Porter et al 25 Porter and McEwan 60 Kaisary et al 35 Cleary et al 51 Bales and Chodak et al 61 Tyrrell et al 62 Chodak et al 26 Bales and Chodak 61 Tyrrell et al 62 Schellhammer et al 27 Schellhammer et al 63 Soloway et al 57 Schellhammer et al 64 Iversen et al 36 Cleary et al 51 Bales and Chodak et al 61 Tyrrell et al 62 da Silva et al 37 Denis et al 58 Rosendahl et al 65 Tannock et al 28 Bloomfield et al 66 Osoba et al 52 Pummer et al 38 Pummer 56 Tyrrell et al 44 Tyrrell 62 Moinpour et al 29 Eisenberger et al 59 Iversen et al 46 Tyrrell et al 62 Duncan et al 31 Pickles et al 67 Fossa et al 40 de Reijke et al 68 clinical significance of the results and give a comprehensive picture of the impact of the medical treatment on patient HRQOL. Other reports appeared to be redundant and/or did not cross reference with other publications.…”